Lund University is celebrating 350 years. Read more on lunduniversity.lu.se

Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

Author:
  • Christoph Varenhorst
  • Stefan James
  • David Erlinge
  • John T. Brandt
  • Oscar Braun
  • Michael Man
  • Agneta Siegbahn
  • Joseph Walker
  • Lars Wallentin
  • Kenneth J. Winters
  • Sandra L. Close
Publishing year: 2009
Language: English
Pages: 1744-1752
Publication/Series: European Heart Journal
Volume: 30
Issue: 14
Document type: Journal article
Publisher: Oxford University Press

Abstract english

The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Ninety-eight patients with coronary artery disease (CAD) taking either clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD) or prasugrel 60 mg LD/10 mg MD were genotyped for variation in six CYP genes. Based on CYP genotype, patients were segregated into two groups: normal function (extensive) metabolizers (EM) and reduced function metabolizers (RM). Plasma active metabolite concentrations were measured at 30 min, 1, 2, 4, and 6 h post-LD and during the MD period on Day 2, Day 14, and Day 29 at 30 min, 1, 2, and 4 h. Vasodilator-stimulated phosphoprotein (VASP) and VerifyNow (TM) P2Y12 were measured predose, 2, and 24 +/- 4 h post-LD and predose during the MD period on Day 14 +/- 3 and Day 29 +/- 3. For clopidogrel, active metabolite exposure was significantly lower (P = 0.0015) and VASP platelet reactivity index (PRI, %) and VerifyNow (TM) P2Y(12) reaction unit (PRU) values were significantly higher (P < 0.05) in the CYP2C19 RM compared with the EM group. For prasugrel, there was no statistically significant difference in active metabolite exposure or pharmacodynamic response between CYP2C19 EM and RM. Variation in the other five genes demonstrated no statistically significant differences in pharmacokinetic or pharmacodynamic responses. Variation in the gene encoding CYP2C19 in patients with stable CAD contributes to reduced exposure to clopidogrel's active metabolite and a corresponding reduction in P2Y(12) inhibition, but has no significant influence on the response to prasugrel.

Keywords

  • Cardiac and Cardiovascular Systems
  • Cytochrome P450 enzymes
  • Clopidogrel
  • Prasugrel
  • CYP2C19
  • Pharmacogenetics

Other

Published
  • ISSN: 1522-9645
E-mail: oscar.braun [at] med.lu.se

Physician

Cardiology

+46 46 17 36 90

32

Project manager

Heart Failure and Mechanical Support

+46 46 17 36 90

32

Research project participant

Molecular Epidemiology and Cardiology

32

Lund University Diabetes Centre, CRC, SUS Malmö, Entrance 72, House 91:12. SE-205 02 Malmö. Telephone: +46 40 39 10 00